相关实验视频

Updated: Sep 15, 2025

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

FRA1通过可操作的转录网络驱动黑色素瘤转移

Xiaonan Xu¹, Manon Chadourne¹, Zulaida Soto-Vargas¹

¹Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA.

bioRxiv : the preprint server for biology

|July 15, 2025

概括

通过调节AXL,CDK6和FSCN1.1等关键基因,FRA1驱动黑色素瘤转移. 抑制这些点为黑色素瘤和其他癌症提供了一个有希望的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
遗传学遗传学是一个

背景情况:

转录失调是黑色素瘤进展的关键因素.
驱动黑色素瘤转移的分子机制尚未完全理解.
确定可操作的治疗点对于黑色素瘤治疗至关重要.

研究的目的:

为了确定黑色素瘤转移的新型分子驱动因素.
阐明FRA1在黑色素瘤进展和转移中的作用.
探索针对FRA1介导途径的治疗潜力.

主要方法:

多omics数据集成以识别FRA1转录目标.
在体外测试以评估基因沉默对黑色素瘤入侵的影响.
在临床前模型中对目标基因的药理抑制.
对基因表达与患者生存数据的相关性分析.

主要成果:

FRA1显著增强了黑色素瘤转移的开始和增长.
AXL,CDK6和FSCN1被确定为FRA1.1的关键转录标.
增加FRA1和其点的表达与黑色素瘤和其他癌症患者的不良结果相关.
沉默或抑制FRA1目标基因 (AXL,CDK6,FSCN1) 取消了入侵并减少了转移性殖民.
药理上抑制CDK6,FSCN1和AXL可以抑制黑色素瘤转移并改善存活率.

结论:

FRA1是黑色素瘤转移的一个关键可操作的驱动因素.
包括AXL,CDK6和FSCN1在内的FRA1介导的转录网络是一个有前途的治疗标.
准这种途径有可能改善黑色素瘤治疗结果,并对其他癌症类型产生更广泛的影响.

关键词:

一个AXLL.在 CDK6 中,CDK6 是 CDK6 的代码.FRA1 FRA1 FRA1 FRA1 FRA1 FRA1 FRA1 FRA1 FRA1 FRA1 FRA1 FRA1 在FSCN1中.黑色素瘤是一种黑色素瘤.转移转移转移转移

更多相关视频

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Author Spotlight: Assessing the Potential of Circulating Tumor Cells in Leptomeningeal Disease Research

Published on: March 29, 2024

Experimental Metastasis Assay

Experimental Metastasis Assay

Published on: August 24, 2010

相关概念视频

MAPK Signaling Cascades

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...